BEX2 是胃癌预后不良的因素，且在癌症干细胞中必要。
BEX2 is poor prognostic factor and required for cancer stemness in gastric cancer.
发表日期：2023 Mar 11
作者：
Akihiro Yasumoto, Haruna Fujimori, Mai Mochizuki, Rie Shibuya-Takahashi, Mao Nakamura-Shima, Norihisa Shindo, Kazunori Yamaguchi, Daisuke Fukushi, Yuta Wakui, Takahiro Sugai, Wataru Iwai, Makoto Abue, Ikuro Sato, Kennichi Satoh, Yu Katayose, Jun Yasuda, Chikashi Shibata, Keiichi Tamai
来源：
Stem Cell Research & Therapy
摘要：
胃癌是全球第五常见的恶性肿瘤。然而，晚期胃癌的靶向治疗仍然有限。在这里，我们报告了BEX2（脑表达X染色体2）作为两个胃癌队列中的不良预后因素。BEX2表达在球体细胞中增加，其沉默减少了aldefluor活性和顺铂耐药性。BEX2被发现以转录方式上调癌干细胞相关基因CHRNB2（胆碱能受体尼古丁酸Beta 2亚基）的表达，其中其沉默也会降低aldefluor活性。这些数据提示了BEX2在胃癌恶性过程中的作用，是一个有前途的治疗靶点。版权所有©2023 Elsevier Inc.。保留所有权利。
Gastric cancer is the fifth most common malignancy worldwide. However, targeted therapy for advanced gastric cancer is still limited. Here, we report BEX2 (Brain expressed X-linked 2) as a poor prognostic factor in two gastric cancer cohorts. BEX2 expression was increased in spheroid cells, and its knockdown decreased aldefluor activity and cisplatin resistance. BEX2 was found to upregulate CHRNB2 (Cholinergic Receptor Nicotinic Beta 2 Subunit) expression, a cancer stemness-related gene, in a transcriptional manner, and the knockdown of which also decreases aldefluor activity. Collectively, these data are suggestive of the role of BEX2 in the malignant process of gastric cancer, and as a promising therapeutic target.Copyright © 2023 Elsevier Inc. All rights reserved.